Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| PR0810KR | Other Identifier | company internal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gadoxetic acid disodium (Primovist, BAY86-4873) | Drug | Patients in daily life clinical practice treatment receiving Primovist according to indication on the label. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety evaluation in real practice (SAE/AE/ADR collection) | After administration |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of contrast effect by imaging after administration | Before administration | |
| Overall contrast effects by combining individual assessment | Before administration | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Korean who take Primovist for liver MRI
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Many Locations | South Korea |
Not provided
| ID | Term |
|---|---|
| C073590 | gadolinium ethoxybenzyl DTPA |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Assessment of contrast enhancement effect |
| After administration |